Agios Pharmaceuticals tapped Brian Goff as CEO Tuesday afternoon. Goff will assume the role on August 8, replacing Jackie Fouse, Ph.D., who will transition to chair of the company’s board of directors.
Goff joins Agios with more than three decades of experience in the biopharma sector, most recently having served as EVP, chief commercial and global operations officer at Alexion Pharmaceuticals. Before that, he served in leadership roles at Neurovance and Baxalta.
“The time is right to evolve our leadership and deepen our genetically defined disease skill set to further drive our ability to develop life-changing treatments,” Fouse said in a statement. “Brian’s strong track record of leading rare disease product launches to drive their impact for patients, building and scaling companies’ rare disease capabilities, and leading high-performing, diverse teams with strong cultures make him the right next leader for Agios.”
